Floatz logo

Recombinant Interleukin-7

Chronic Myelogenous Leukemia, BCR-ABL1 Positive

M.D. Anderson Cancer CenterPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

86 Active assets in the Chronic Myelogenous Leukemia, BCR-ABL1 Positive cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
City of Hope Medical Center
Phase 3BBB
Fludarabine
Fred Hutchinson Cancer Center
Phase 3BBB
Nilotinib
Novartis Pharmaceuticals
Phase 4BBB
Therapeutic Allogeneic Lymphocytes
University of Chicago
Phase 2BBB
Sargramostim
Virginia Commonwealth University
Phase 2BBB

View all 50 →

Same molecule, other indications

Recombinant Interleukin-7 is also rated in:

myeloproliferative neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →
myelodysplastic syndromeDormant
CC
Indicative ·
46 / 100
View asset →
cancer of unknown primary siteDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →